Viking Therapeutics (XTER:1VT) 1-Year Share Buyback Ratio: -2.90% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:1VT Viking Therapeutics Inc XTER:1VT
34 GF Score
Price €28.30
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics 1-Year Share Buyback Ratio?

Viking Therapeutics XTER:1VT -3.90% 34 1-Year Share Buyback Ratio is -2.90 as of Jun. 2026. GuruFocus rates XTER:1VT with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,110 Biotechnology companies, Viking Therapeutics ranks better than 71.17% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Viking Therapeutics's current 1-Year Share Buyback Ratio was -2.90%.

XTER:1VT's 1-Year Share Buyback Ratio is ranked better than
71.17% of 1110 companies
in the Biotechnology industry
Industry Median: -14.55 vs XTER:1VT: -2.90

Viking Therapeutics  (XTER:1VT) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Viking Therapeutics 1-Year Share Buyback Ratio Related Terms

XTER:1VT vs : 1-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Viking Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics 1-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's 1-Year Share Buyback Ratio falls into.


XTER:1VT
34GF Score
Viking Therapeutics Inc XTER:1VT
1-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics 1-Year Share Buyback Ratio Calculation

Viking Therapeutics's 1-Year Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Jun. 2025 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Jun. 2025 )
=(112.330 - 116.653) / 112.330
=-3.8%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -2.90 mean?
Viking Therapeutics (XTER:1VT) has a 1-Year Share Buyback Ratio of -2.90 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #320 out of 1110 companies in the Biotechnology industry, placing it in the top 28.8%.
Is Viking Therapeutics' 1-Year Share Buyback Ratio too high?
Viking Therapeutics' current 1-Year Share Buyback Ratio is -2.90. Based on the distribution chart, Viking Therapeutics ranks #320 out of 1110 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viking Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' 1-Year Share Buyback Ratio compare to ?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #320 out of 1110 companies for 1-Year Share Buyback Ratio. This puts Viking Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Viking Therapeutics and its competitors. Viking Therapeutics's current 1-Year Share Buyback Ratio is -2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (XTER:1VT) has a current 1-Year Share Buyback Ratio of -2.90. The current 1-Year Share Buyback Ratio is -2.90. Viking Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Viking Therapeutics (XTER:1VT), the current 1-Year Share Buyback Ratio is -2.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Comparable Companies
Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
34GF Score

Get the complete analysis for XTER:1VT

1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.30
Price